There is evidence that members of racial and ethnic minority groups may be less likely to receive palliative care compared to non-Hispanic Whites. This may be due to either to different treatment of minority patients by physicians, or from less utilization of palliative care at the relatively small number of hospitals which treat a large portion of minority patients. To assess the impact of site of care on disparities in palliative care, we assessed whether receipt of palliative care among men with metastatic prostate cancer differed at hospitals which predominantly treat minority patients.
INTRODUCTION AND OBJECTIVES:
There is evidence that members of racial and ethnic minority groups may be less likely to receive palliative care compared to non-Hispanic Whites. This may be due to either to different treatment of minority patients by physicians, or from less utilization of palliative care at the relatively small number of hospitals which treat a large portion of minority patients. To assess the impact of site of care on disparities in palliative care, we assessed whether receipt of palliative care among men with metastatic prostate cancer differed at hospitals which predominantly treat minority patients.
METHODS: We abstracted data on men >40 years of age, with metastatic prostate cancer within the National Cancer Database. The receipt of palliative care was compared in each racial group. Hospitals in the top decile in terms of the proportion of Black and Hispanic patients were defined as minority-serving hospitals (MSHs). A multilevel logistic regression model estimating the odds of receiving palliative care based on MSH status was fit, adjusting for year of diagnosis, sex, race, insurance, income, and education, with a hospital-level random intercept to account for unmeasured hospital characteristics.
RESULTS: Our study cohort consisted of 44,521 men with metastatic prostate cancer. The average age was 71.3 (95% CI 71.1-71.6). Of these men, 7096 (15.9%) were treated at MSHs. The proportion of men of receiving palliative care differed based on race: Overall 15.9% of white men received palliative care for prostate cancer, whereas only 14.7% of black men and 12.0% of Hispanics received palliative care (p <0.001). In our model adjusting for clinical and demographic variables, and minority serving hospital status, MSH status had a large and statistically significant association with lower odds of palliative care (OR 0.67 95% CI 0.55-0.82), whereas Black and Hispanic race did not (OR 1.00 95% 0.91-1.09) and (0.98 95% 0.85-1.13).
CONCLUSIONS: In our adjusted model, treatment at an MSH had a large and statistically significant impact on receipt of palliative care; patient race did not. These findings suggest that the site of care, may account for much of the observed race-based disparities in palliative care in prostate cancer. Targeting MSHs may represent an effective strategy to combat disparities in palliative care. 
PD15-09 TROMBONE: TESTING RADICAL PROSTATECTOMY IN MEN WITH OLIGOMETASTATIC PROSTATE CANCER THAT HAS SPREAD TO THE BONE-A RANDOMIZED CONTROLLED FEASIBILITY TRIAL
has not previously been examined in a RCT. We report the world's first RCT, TRoMbone, on the safety and feasibility of randomization to systemic therapy plus RP in synchronous oligo-metastatic prostate cancer.
TRoMbone aimed to recruit 50 men over a 12-month period and was co-ordinated by the Surgical Intervention Trials Unit at the University of Oxford.
METHODS: The initial Protocol randomized men with synchronous oligo-metastatic prostate cancer (1-3 skeletal metastases on conventional imaging) who were <75 years old and ECOG PS 0-1, to radical prostatectomy and extended pelvic lymphadenectomy within 3 months of starting standard care systemic therapy (Intervention) versus standard care systemic therapy alone (Control). The Protocol was amended to allow patients to have Docetaxel prior to RP, and to increase the number of recruitment sites from 3 to 9.
RESULTS: Of 176 patients screened, 71 were eligible; of those, 51 (71.8%) were randomized. High recruitment rates were achieved with use of a quintet recruitment investigation (QRI). This identified the commonest causes of non-recruitment as: patients not wanting surgery; lack of clinician equipoise; and, (before the Protocol Amendment; PA) inability to have Docetaxel preoperatively. As a result of the PA, recruitment completed 4 months ahead of schedule with 7/9 (77.8%) sites successfully recruiting at least one patient (Figure) . 8 surgeons performed the Intervention. Thus far, roughly half of the Intervention patients had received Docetaxel preoperatively, and all had received androgen deprivation therapy. 1 patient allocated to the Intervention did not undergo RP, as he felt too unwell post-Docetaxel. 1 patient allocated to the Control arm refused standard-care treatment, as he preferred to try Homeopathy. 100% RPs were conducted with robotic assistance, no cases were abandoned, and the only complication to date (in 18 patients) is a rectal injury (repaired intraoperatively with primary closure; that same patient was the only one who required a blood transfusion). Zero cases were abandoned, and there were no postoperative complications. Quality-of-life data demonstrated equivalence in EQ5D scores between the Control and Intervention groups, and satisfaction scores were high even in those who received ADT, Docetaxel, and RP.
CONCLUSIONS: It is feasible to randomize UK men with synchronous oligo-metastatic prostate cancer to standard care systemic therapy versus that plus locally-directed surgery. Interim outcomes suggest the procedure is safe and technically feasible, and a full RCT is being planned. METHODS: We retrospectively enrolled 703 PCa patients with biochemical recurrence (BCR) after radical prostatectomy (n[684) and primary radiotherapy (n[19) . Each man underwent 68Ga-PSMA PET/ CT to identify the site of recurrence. Patients were stratified according to different clinical settings of recurrence: first PSA relapse (group 1, n[325), BCR after salvage therapy (group 2, n[241), PSA persistence after primary therapy (group 3, n[76) and disease progression before starting systemic therapies (group 4, n[61) . We assessed the detection rate of 68Ga-PSMA PET/CT in overall population and in each subgroup. Multivariate logistic regressions were used to determine which co-variates (including ISUP group, PSA at 68Ga-PSMA PET/CT, PSA doubling time, ongoing androgen deprivation therapy [ADT] at 68Ga-PSMA PET/CT, time to recurrence and the clinical setting) independently predict a positive 68Ga-PSMA PET/CT. Finally, regression-based coefficients were used to develop a nomogram predicting positive 68Ga-PSMA PET/CT and 200 bootstrap resamples were used for internal validation.
RESULTS: Table 1 reports overall patients characteristics. Median PSA at 68Ga-PSMA PET/CT was 0.7 ng/ml (IQR 0.4-1.3). Overall, 116 (16.5 %) men were on-going with ADT at the time of 68Ga-PSMA PET/CT. Median time to BCR was 21 months (IQR 9-49); median PSA doubling time was 6 months (IQR 4-10). The overall detection rate of 68Ga-PSMA PET/CT was 51.2 %. Table 2 reports PET-CT diagnostic performance among the different groups: detection rate was 40.3 %, 54 %, 60.5% and 86.9 % in group 1, 2, 3 and 4, respectively (p<0.001). At multivariable analysis ISUP grade group, PSA at 68Ga-PSMA PET/CT, PSA doubling time and the clinical setting were found to be independent predictors of positive 68Ga-PSMA PET/CT results (all p 0.04). A nomogram based on covariates included in the multivariate model demonstrated bootstrapcorrected predictive accuracy of 82%.
CONCLUSIONS: Our nomogram could help physician to select patients with different scenario of recurrence who may benefit from 68Ga-PSMA PET/CT restaging.
